Neratinib in HER-2-positive breast cancer: results to date and clinical usefulness

The management of HER-2-positive breast cancer has improved significantly with the use of targeted agents to the HER-2 signaling pathway. Despite the improved survival achieved with the use of trastuzumab and chemotherapy in both the adjuvant and metastatic setting, patients may still recur or progr...

Full description

Bibliographic Details
Main Author: Arlene Chan
Format: Article
Language:English
Published: SAGE Publishing 2016-09-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/1758834016656494